Le X, Patel JD, Shum E, Baik C, et al. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naive EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J Clin Oncol 2024 Oct 8:JCO2400533. doi: 10.1200/JCO.24.00533.
PMID: 39378386